Filing Flows › Caribou Biosciences (CRBU) › Q3 2025
Caribou Biosciences (CRBU) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 12, 2025
Caribou Biosciences (CRBU) reported revenue of $2.2M for the third quarter 2025 (Q3 2025), +9% from a year earlier and -18% from the quarter before.
Caribou Biosciences, Q3 2025: revenue $2.2M (+9% year over year), net loss $27.5M, operating cash flow −$25.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.2M | -18% | +9% |
| Operating profit | −$29.4M | — | — |
| Net earnings | −$27.5M | — | — |
| Operating cash flow | −$25.2M | — | — |
What changed
Revenue was $2.2M in Q3 2025, up 9% year over year and down 18% from the previous quarter.
Operating costs exceeded revenue by $29.4M, an operating margin of -1337.6%. Total costs fell 22% while revenue rose 9%. The quarter ended with a net loss of $27.5M, narrower than the previous quarter's $54.1M loss.
Operating cash flow was −$25.2M. Non-cash charges added back $631K of depreciation and amortization and $2.9M of share-based compensation. Capital expenditures of $115K exceeded it, leaving free cash flow of −$25.3M.
Questions
What was Caribou Biosciences' revenue in the third quarter 2025?
Caribou Biosciences (CRBU) reported revenue of $2.2M for the third quarter 2025 (Q3 2025), +9% from a year earlier and -18% from the quarter before.